Syndax Pharmaceuticals, Inc. <SNDX.O>: BofA Global Research cuts price objective to $26 from $29
SNDX•Related News
Avidbank Holdings President Jonathan Dale files initial beneficial ownership statement
AVBH•
LPL Financial’s Strategic Wealth unit adds WestKai Private Wealth with $400 million in assets
LPLA•
Booking Holdings Inc. <BKNG.O>: B. Riley raises target price to $274 from $264
BKNG•
Fortress Biotech unit Journey Medical to report Q2 results, host conference call
DERM•
NNN REIT Q2 FY26 core FFO per share rises 6% to $0.89; revenue increases to $244.27 million
NNN•